Drug Trial Radar · NCT00288704
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Last checked: Nov 20, 2026Latest source record: Dec 6, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Dec 2005
Primary completion
Jun 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Feb 8, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1). These mutations result in the body's overproduction of interleukin-1 (IL-1), a protein that stimulates the inflammatory process. IL-1 Trap (rilonacept) was designed to bind to the interleukin-1 cytokine and prevent it from binding to its receptors in the body.
Conditions
- Familial Cold Autoinflammatory Syndrome (FCAS)
- Familial Cold Urticaria
- Muckle-Wells Syndrome (MWS)
- Genetic Diseases, Inborn
Interventions
rilonacept 160 mgDrug
Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
PlaceboDrug
Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
rilonacept 160 mgDrug
Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS)Time frame: Baseline (Days -21 to -1) and Week 6 (Days 21-42)
- Mean Change in Key Symptom Score (KSS) From Week 15 to Week 24 (During the Randomized Withdrawal Phase or Part B)Time frame: Week 15 through Week 24 (randomized withdrawal)
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Palm Desert, California
Site not named
Upland, California
Site not named
Jacksonville, Florida
Site not named
Stuart, Florida
Site not named
Atlanta, Georgia
Site not named
Columbus, Georgia
Site not named
Aurora, Illinois
Site not named
Louisville, Kentucky
Site not named
Shreveport, Louisiana
Site not named
Chesterfield, Michigan
Site not named
St Louis, Missouri
Site not named
New York, New York
Site not named
Raleigh, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Duncansville, Pennsylvania
Site not named
Columbia, South Carolina
Site not named
Greer, South Carolina
Site not named
Chattanooga, Tennessee
Site not named
Dallas, Texas
Site not named
Waco, Texas
Site not named
Cedar City, Utah
Site not named
Forest, Virginia
Site not named
Lakewood, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.